Pacira BioSciences, Inc. (PCRX) stock analysis
PCRX · Pacira BioSciences, Inc.
Latest recorded price: USD 36.48
Model-estimated fair value: USD 66.92. This assumption-based estimate is for general research and is not investment advice.
Sector and industry: Healthcare · Drug Manufacturers - Specialty & Generic
At $36.48, PCRX trades 45.5% below the model's base-case value of $66.92. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $51.98 in the conservative case and $84.17 in the optimistic case, with a valuation confidence score of 75/100. About 73% of the value comes from the terminal value, so the result is sensitive to long-term growth and discount-rate assumptions. Fiscal 2025 figures: revenue growth 10.3%, free cash flow margin 18.8%, ROIC 2.2%. The model flags 1 risk signal for this company.